Clinical Edge Journal Scan

Is migraine related to adverse pregnancy outcomes?


 

Key clinical point: With self-reported migraine being associated with 26% higher odds of adverse pregnancy outcomes (APO), it may be a significant risk factor for APO.

Major finding: After adjusting for confounding factors, women with migraine showed increased odds of any APO (adjusted odds ratio 1.26; 95% CI 1.12-1.41).

Study details: This was a multicenter prospective study, nuMoM2b, including 9450 nulliparous singleton pregnant women in early gestation, of which 1752 self-reported migraine at the first-trimester visit.

Disclosures: The nuMoM2b study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Case Western Reserve University, and Columbia University, among others. EC Miller and NA Bello declared receiving financial support from various sources.

Source: Miller EC et al. Migraine and adverse pregnancy outcomes: the nuMoM2b study. Am J Obstet Gynecol. 2022 (May 2). Doi: 10.1016/j.ajog.2022.04.049

Recommended Reading

Meta-analysis backs the clinically significant effects of transcutaneous nerve stimulation in migraine
Migraine ICYMI
CGRPs: They’ve Been a Long Time Coming
Migraine ICYMI
Safety Concerns with CGRP Monoclonal Antibodies
Migraine ICYMI
Clinical Edge Journal Scan Commentary: Migraine May 2022
Migraine ICYMI
Fremanezumab can prevent migraine across a broad real-world patient population
Migraine ICYMI
Evidence of real-world effectiveness of erenumab against chronic migraine
Migraine ICYMI
Migraine: Suboptimal first-dose responders may benefit from a second dose of eptinezumab
Migraine ICYMI
Galcanezumab reduces acute headache medication use in treatment-resistant migraine
Migraine ICYMI
Migraine: Ubrogepant therapy yields favorable 2-hour outcomes in triptan insufficient responders
Migraine ICYMI
Subcutaneous injection of diclofenac sodium is effective against acute migraine
Migraine ICYMI